Breast Cancer Diagnosis Articles & Analysis
36 news found
CEM is an emerging modality that combines digital mammography with the administration of a contrast agent, such as Ultravist, to support the diagnosis of breast cancer and guide treatment decisions. The approval expands Bayer’s radiology portfolio, which includes contrast media, injectors as well as digital and artificial intelligence (AI) ...
ByBayer AG
Cirdan are delighted to announce that together with Queen’s University Belfast and our KTP Associate and Senior AI Engineer, Jonathan Armstrong, we have been selected as the winners of the Best KTP project by Innovate UK. Innovate UK’s Best Knowledge Transfer Partnership award honours the KTP which has brought the greatest benefits to all three participants, exceeding the expectations ...
October marks a month dedicated to a cause close to the core of everything which we do at Cirdan: Breast Cancer Awareness. This month will see a surge in activism surrounding breast cancer awareness and a push for finding a cure from around the globe. The fight to treat and cure breast cancer continues constantly, and we pride ourselves in taking part in the fight to save lives. Breast cancer ...
Cirdan are delighted to announce that together with Queen’s University Belfast and our KTP Associate and Senior AI Engineer, Jonathan Armstrong, we have been shortlisted for Innovate UK’s esteemed Best Knowledge Transfer Partnership Award. Innovate UK’s Best Knowledge Transfer Partnership award honours the KTP which has brought the greatest benefits to all three participants, ...
Food and Drug Administration for Koios DS (Decision Support) Breast 2.0, a new version of its machine learning based platform that assists physicians in the classification and diagnosis of breast cancer. ...
Prelude Corporation (PreludeDx, a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced compelling results in 926 women diagnosed with ductal carcinoma in situ (DCIS). The new information was presented in an oral abstract session at the American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place, Chicago, IL. The results of the study ...
Prelude Corporation (PreludeDx, a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that its study in 926 DCIS patients demonstrating the clinical utility of DCISionRT? was selected for an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. The results evaluating the association of DCISionRT, a predictive DCIS ...
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced compelling results in 926 women diagnosed with ductal carcinoma in situ (DCIS). The new information was presented in an oral presentation at the American Society of Breast Surgeons (ASBrS) 23rd Annual Meeting, held on April 6 - 10, 2022 at Wynn Las Vegas, NV. The ...
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that it has closed a $20 million funding round led by Evidity Health Capital and joined by existing and new investors including BlueStone Venture Partners. Alejandro Sanchez, Managing Director of Evidity Health Capital, will be joining PreludeDx’s Board of ...
bout two years after the outbreak of COVID-19, many resources are still being used in the fight against this new virus. Nevertheless, the number of breast cancer cases in Italy are still very high: according to the report “The numbers of cancer in Italy”, published by AIRTUM and AIOM, in 2020 about 55.000 new cases were diagnosed in ...
(Seno Medical), a Texas-based medical imaging company developing breakthrough breast cancer diagnostic technology, announced an educational partnership supporting Worldwide Breast Cancer’s “Know Your Lemons” campaign starting with the Netherlands, which has one of the highest breast ...
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it will be presenting data comparing DCISionRT? and its integrated Residual Risk subtype (RRt) with traditional clinicopathology features at the 39th Annual Miami Breast Cancer Conference (MBCC), being held on March 3 – 6, 2022 at the Fontainebleau Miami ...
"I am thrilled to be part of such an impressive team of scientists, researchers and developers focused on early breast cancer detection, prediction and diagnosis. AI has matured since the early 2000s, and is now poised to be a leading clinical decision support tool, assisting radiologists and other clinicians in the global fight to improve ...
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced the publication of SweDCIS randomized clinical trial data in the Special Issue: Updates on Breast Cancer edition of Cancers. The randomized study demonstrates that the DCISionRT test predicts radiation benefit for reducing 10-year local invasive breast cancer risk. ...
“Clinical research has shown that delays in breast cancer diagnosis can lead to worse outcomes, including the risk of the cancer metastasizing, decreased survivorship, and increased treatment costs,” comments Peter Kecskemethy, Kheiron’s Chief Executive Officer. ...
Optina’s Retinal Deep Phenotyping™ platform obtained FDA Breakthrough Device Designation status in 2019 for its non-invasive and more accessible test to improve diagnosis accuracy and the management of patients undergoing evaluation for Alzheimer’s disease (AD). ...
Aidoc’s comprehensive AI continues to expand to cover the majority of radiology adult subspecialties Aidoc, the leading provider of AI for medical imaging, and ScreenPoint Medical, leader of deep learning AI for 2D and 3D mammography, today announced a collaboration which will incorporate ScreenPoint’s capabilities into Aidoc’s platform. Breast imaging ...
ByAidoc
In Nigeria, breast cancer is becoming the major health problem, representing nearly 25% of all new cancer diagnoses in the country. The parties at the signing ceremony have agreed to co-develop Breast Cancer Centers of Excellence which will deliver comprehensive, compassionate breast ...
IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced the advancement of its regulatory strategy in China with the submission of an amendment to the registration certificate for the IceSense3® system, which was granted ...
“It goes to show how excited people are about our mission and demonstrates people’s desire to help millions of women around the world avoid later-stage breast cancer diagnoses.” The company aims to raise a maximum of $5M via Republic. ...